

APR. 5. 2006 10:22AM AVENTIS US PAT DEPT  
TO: US CENTRALIZED USPTO

RECEIVED  
CENTRAL FAX CENTER

NO. 3097 P. 1

APR 05 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

18

Application Number

10/751,545

Filing Date

January 05, 2004

First Named Inventor

Otmar KLINGLER et al.

Art Unit

1624

Examiner Name

RAO, Deepak R.

Attorney Docket Number

DEAV2003/0002 US NP

### ENCLOSURES (Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)



Reply to Missing Parts/  
Incomplete Application



Reply to Missing Parts  
under 37 CFR 1.52 or 1.53



Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a  
Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

Remarks



After Allowance Communication to TC



Appeal Communication to Board  
of Appeals and Interferences



Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)



Proprietary Information



Status Letter



Other Enclosure(s) (please identify  
below):

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

AVENTIS PHARMACEUTICALS INC.

Signature

Printed name

Joseph D. Rossi

Date

April 05, 2006

Reg. No.

47,038

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 18)

Signature

Typed or printed name

Paul Irvine

Date

April 05, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APR. 5. 2006 10:22AM

AVENTIS US PAT DEPT

**RECEIVED  
CENTRAL FAX CENTER**

NO. 3097 P. 2

**DEAV2003/0002 US NP**

**APR 05 2006**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLINGLER, et al.**

Examiner: D. Rao

Art Unit: 1624

Application No.: 10/751,545

Filed: January 5, 2004

Title: **SELECTIVE MMP-13 INHIBITORS**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

April 5, 2006

Date of Transmission

Signature

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO ACTION PURSUANT TO 37 CFR § 1.111**

In response to the Office Action dated January 5, 2006 ("the Action"), reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- ☒ **Amendments to the Claims** are reflected in the Listing of Claims, which begins on page 2 of this paper.
- ☒ **Remarks/Arguments** begin on page 14 of this paper.